Alpha 2.0
Login Register
» Authors » Michael Emig

Michael Emig

Explore the profile of Michael Emig including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 13
Citations 2094
Followers 0
Related Specialties
Oncology
Gastroenterology
General Medicine
Top 10 Co-Authors
Kei Muro
Yasuhiro Shimada
Atsushi Ohtsu
Eric Van Cutsem
Gyorgy Bodoky
Rudiger Hehlmann
Kumari Chandrawansa
Andreas Hochhaus
Astra M Liepa
Ian Chau
Published In
Clin Cancer Res
Anticancer Drugs
Proc Natl Acad Sci U S A
Lancet Oncol
J Gastric Cancer
Affiliations
Soon will be listed here.
Recent Articles
1.
First-in-Human Phase 1 study of a CD16A bispecific innate cell engager, AFM24, targeting EGFR-expressing solid tumors
El-Khoueiry A, Saavedra O, Thomas J, Livings C, Garralda E, Hintzen G, et al.
Clin Cancer Res . 2025 Jan; PMID: 39846810
Purpose: Innate immune cell-based therapies have shown promising antitumor activity against solid and hematologic malignancies. AFM24, a bispecific innate cell engager, binds CD16A on natural killer (NK) cells/macrophages and EGFR...
2.
A Phase II Study of Acimtamig (AFM13) in Patients with CD30-Positive, Relapsed, or Refractory Peripheral T-cell Lymphomas
Kim W, Shortt J, Zinzani P, Mikhailova N, Radeski D, Ribrag V, et al.
Clin Cancer Res . 2024 Nov; 31(1):65-73. PMID: 39531538
Purpose: Patients with relapsed or refractory (R/R) peripheral T-cell lymphoma (PTCL) generally have poor prognoses and limited treatment options. This study evaluated the efficacy of a novel CD30/CD16A bispecific innate...
3.
Tumor Response and Symptom Palliation from RAINBOW, a Phase III Trial of Ramucirumab Plus Paclitaxel in Previously Treated Advanced Gastric Cancer
Cascinu S, Bodoky G, Muro K, Van Cutsem E, Oh S, Folprecht G, et al.
Oncologist . 2020 Dec; 26(3):e414-e424. PMID: 33274542
Background: In the intent-to-treat (ITT) population of the RAINBOW study, objective response rate (ORR) was 28% and 16% in the ramucirumab and control arms, respectively. To further characterize tumor response,...
4.
Age does not influence efficacy of ramucirumab in advanced gastric cancer: Subgroup analyses of REGARD and RAINBOW
Muro K, Cho J, Bodoky G, Goswami C, Chao Y, Dos Santos L, et al.
J Gastroenterol Hepatol . 2017 Sep; 33(4):814-824. PMID: 28960444
Background And Aim: REGARD and RAINBOW were global, phase 3, randomized, double-blind trials of second-line ramucirumab for metastatic gastric or gastroesophageal junction adenocarcinoma. Exploratory subgroup analyses were described to assess...
5.
Prognostic Factor Analysis of Overall Survival in Gastric Cancer from Two Phase III Studies of Second-line Ramucirumab (REGARD and RAINBOW) Using Pooled Patient Data
Fuchs C, Muro K, Tomasek J, Van Cutsem E, Cho J, Oh S, et al.
J Gastric Cancer . 2017 Jul; 17(2):132-144. PMID: 28680718
Purpose: To identify baseline prognostic factors for survival in patients with disease progression, during or after chemotherapy for the treatment of advanced gastric or gastroesophageal junction (GEJ) cancer. Materials And...
6.
Biomarker analyses in REGARD gastric/GEJ carcinoma patients treated with VEGFR2-targeted antibody ramucirumab
Fuchs C, Tabernero J, Tomasek J, Chau I, Melichar B, Safran H, et al.
Br J Cancer . 2016 Sep; 115(8):974-982. PMID: 27623234
Background: Angiogenesis inhibition is an important strategy for cancer treatment. Ramucirumab, a human IgG1 monoclonal antibody that targets VEGF receptor 2 (VEGFR2), inhibits VEGF-A, -C, -D binding and endothelial cell...
7.
Subgroup analyses of the safety and efficacy of ramucirumab in Japanese and Western patients in RAINBOW: a randomized clinical trial in second-line treatment of gastric cancer
Shitara K, Muro K, Shimada Y, Hironaka S, Sugimoto N, Komatsu Y, et al.
Gastric Cancer . 2015 Oct; 19(3):927-38. PMID: 26510663
Background: We evaluated the safety and efficacy of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients previously treated for advanced gastric or gastroesophageal junction adenocarcinoma in Japanese and Western...
8.
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
Wilke H, Muro K, Van Cutsem E, Oh S, Bodoky G, Shimada Y, et al.
Lancet Oncol . 2014 Sep; 15(11):1224-35. PMID: 25240821
Background: VEGFR-2 has a role in gastric cancer pathogenesis and progression. We assessed whether ramucirumab, a monoclonal antibody VEGFR-2 antagonist, in combination with paclitaxel would increase overall survival in patients...
9.
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial
Pirker R, Pereira J, Szczesna A, von Pawel J, Krzakowski M, Ramlau R, et al.
Lancet . 2009 May; 373(9674):1525-31. PMID: 19410716
Background: Use of cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor (EGFR), has the potential to increase survival in patients with advanced non-small-cell lung cancer. We therefore compared...
10.
Leukocytoclastic vasculitis and acute renal failure after influenza vaccination in an elderly patient with myelodysplastic syndrome
Ulm S, Hummel M, Emig M, Barreto-Miranda M, Back W, Reiter A, et al.
Onkologie . 2006 Oct; 29(10):470-2. PMID: 17028456
Background: Influenza vaccination is recommended for individuals over 65 years of age and for all patients with chronic diseases who are at risk. Side effects which are seen in 1-10%...